Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma

Oncology Reviews

Volumn 2, Issue 3, 2008, Pages 183-193

  Hwu, Wen Jen ^a   Ayala, Ana E ^a   Hernandez, Ingrid M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Interferon; Melanoma; O6 methylguanine DNA methyltransferase; Temozolomide; Thalidomide

Indexed keywords

EID: 67650546645     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-008-0073-1     Document Type: Review

References (57)

1. Legha SS (1997) Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin Oncol 24[Suppl4]: S39-S43
2. Legha SS, Ring S, Eton O et al (1998) Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16:1752-1759 (Pubitemid 28234719)
3. Ives NJ, Stowe RL, Lorigan P, Wheatley K (2007) Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 25:5426-5434 (Pubitemid 350232219)
4. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445:851-857
5. Atkins MB, Lotze MT, Dutcher JP et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116 (Pubitemid 29318842)
6. Coates AS (1992) Systemic chemotherapy for malignant melanoma. World J Surg 16:277-281
7. Middleton MR, Grob JJ, Aaronson N et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166 (Pubitemid 30036349)
8. Stevens MF, Hickman JA, Langdon SP et al (1987) Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo[ 5,1-d]-1,2,3,5- tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47:5846-5852 (Pubitemid 18018717)
9. Newlands ES, Stevens MF, Wedge SR et al (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35-61 (Pubitemid 27273454)
10. Agarwala SS, Kirkwood JM (2000) Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 5:144-151 (Pubitemid 30238234)
11. Paul MJ, Summers Y, Calvert AH et al (2002) Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 12:175-178 (Pubitemid 34478459)
12. Bleehen NM, Newlands ES, Lee SM et al (1995) Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13:910-913
13. Kiebert GM, Jonas DL, Middleton MR (2003) Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest 21:821-829 (Pubitemid 38055978)
14. Quirt I, Verma S, Petrella T et al (2007) Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 12:1114-1123 (Pubitemid 350007023)
15. Avril MF, Aamdal S, Grob JJ et al (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22:1118-1125 (Pubitemid 41095046)
16. Amaravadi RK, Flaherty KT (2007) Targeted therapy for metastatic melanoma. Clin Adv Hematol Oncol 5:386-394
17. Danson S, Lorigan P (2005) Improving outcomes in advanced malignant melanoma: update on systemic therapy. Drugs 65:733-743 (Pubitemid 40593623)
18. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085 (Pubitemid 24139577)
19. Haslett PA, Corral LG, Albert M, Kaplan G (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187:1885-1892 (Pubitemid 28262451)
20. Fanelli M, Sarmiento R, Gattuso D et al (2003) Thalidomide: a new anticancer drug? Expert Opin Investig Drugs 12:1211-1225 (Pubitemid 36857209)
21. Newlands ES, Blackledge GR, Slack JA et al (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65:287-291
22. Brock CS, Newlands ES, Wedge SR et al (1998) Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58:4363-4367 (Pubitemid 28450038)
23. Tolcher AW, Gerson SL, Denis L et al (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004-1011 (Pubitemid 36560766)
24. Su YB, Sohn S, Krown SE et al (2004) Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22:610-616 (Pubitemid 41095063)
25. Liu L, Taverna P, Whitacre CM, Chatterjee S et al (1999) Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res 5:2908-2917 (Pubitemid 29493970)
26. Bignami M, O'Driscoll M, Aquilina G, Karran P (2000) Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. Mutat Res 462:71-82 (Pubitemid 30190215)
27. Roos WP, Batista LF, Naumann SC et al (2007) Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26:186-197 (Pubitemid 46095730)
28. Dolan ME, Stine L, Mitchell RB, Moschel RC, Pegg AE (1990) Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4- methylcyclohexyl)-1-nitrosourea. Cancer Commun 2:371-377
29. Agarwala SS, Kirkwood JM, Gore M et al (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22:2101-2107 (Pubitemid 41095143)
30. Bafaloukos D, Tsoutsos D, Kalofonos H et al (2005) Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 16:950-957 (Pubitemid 40903922)
31. Kaufmann R, Spieth K, Leiter U et al (2005) Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 23:9001-9007 (Pubitemid 46211484)
32. Middleton MR, Lunn JM, Morris C et al (1998) O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 78:1199-1202 (Pubitemid 28479151)
33. Middleton MR, Lee SM, Arance A, Wood M et al (2000) O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer 88:469-473
34. Danson S, Lorigan P, Arance A et al (2003) Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 21:2551-2557 (Pubitemid 46606337)
35. Margolin K, Atkins MB, Thompson JA et al (2002) Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 128:214-218 (Pubitemid 34280379)
36. Rietschel P, Wolchok JD, Krown S et al (2008) Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 26:2299-2304
37. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
38. Hwu W-J, Panageas KS, Menell JH et al (2006) Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer 106:2445-2451 (Pubitemid 43787669)
39. Richtig E, Hofmann-Wellenhof R, Pehamberger H et al (2004) Temozolomide and interferon alpha 2b in metastatic melanoma stage IV. Br J Dermatol 151:91-98 (Pubitemid 39061284)
40. Ridolfi R, Romanini A, Sileni VC et al (2004) Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. Melanoma Res 14:295-299 (Pubitemid 39159143)
41. Bukowski RM, Tendler C, Cutler D et al (2002) Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 95:389-396 (Pubitemid 34787605)
42. Atkins MB, Sosman J, Agarwala S et al (2005) A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma [abstract]. J Clin Oncol 23[Suppl]:723s. Abstract 7552
43. Hwu W-J, Krown SE, Menell JH et al (2003) Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 21:3351-3356 (Pubitemid 46606269)
44. Hwu W-J, Lis E, Menell JH et al (2005) Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103:2590-2597 (Pubitemid 40800539)
45. Laber DA, Okeke RI, Arce-Lara C et al (2006) A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. J Cancer Res Clin Oncol 132:611-616 (Pubitemid 44078530)
46. Clark J, Moon J, Hutchins LF et al (2008) Phase II trial of combination thalidomide (thal) plus temozolomide (TMZ [TT]), in patients with metastatic malignant melanoma (MMM): Southwest Oncology Group S0508. J Clin Oncol 26:2007
47. Liu L, Cao Y, Chen C et al (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-11858 (Pubitemid 46094197)
48. Eisen T, Ahmad T, Flaherty KT et al (2006) Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 95:581-586 (Pubitemid 44325897)
49. Amaravadi RK, Schuchter LM, McDermott DF et al (2007) Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma [abstract]. J Clin Oncol 25[suppl]:478s. Abstract 8527
50. Agarwala SS, Keilholz U, Hogg D et al (2007) Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma [abstract]. J Clin Oncol 25[suppl]:474s. Abstract 8510
51. Eisen T, Marais R, Affolter A et al (2007) An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma [abstract]. J Clin Oncol 25[Suppl]:479s. Abstract 8529
52. McDermott DF, Sosman JA, Hodi FS et al (2007) Randomized phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma [abstract]. J Clin Oncol 25[Suppl]:474s. Abstract 8511
53. Ranson M, Hersey P, Thompson D et al (2007) Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 25:2540-2545 (Pubitemid 47041227)
54. Plummer ER, Calvert H (2007) Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy. Clin Cancer Res 13:6252-6256 (Pubitemid 350075012)
55. Plummer ER, Middleton MR, Jones C et al (2005) Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 11:3402-3409 (Pubitemid 40627893)
56. Plummer R, Middleton M, Wilson R, et al (2005) First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors [abstract]. J Clin Oncol 23[Suppl]:208s. Abstract 3065
57. Plummer R, Lorigan P, Evans J, et al (2006) First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM) [abstract]. J Clin Oncol 24[Suppl]:456s.